Drugs / Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05465902 | Jul 2023 → Nov 2024 | COVID-19 | WestVac Biopharma Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05770180 | Mar → Jul 2023 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06175494 Comparator | Dec 2023 → Jul 2024 | COVID-19 | WestVac Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant COVID-19 Variant Vaccine (Sf9 Cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06175494 ↗ |
| Modality | Vaccine | “Recombinant COVID-19 variant Vaccine (Sf9 Cell)” NCT05465902 ↗ |
| Route | Intramuscular | “1dose, Intramuscular Injection” NCT05465902 ↗ |